Home > Publications database > ARID1A mutations in lung cancer: biology, prognostic role, and therapeutic implications. |
Journal Article (Review Article) | DKFZ-2023-00969 |
; ; ; ; ; ; ;
2023
Elsevier Science
Amsterdam [u.a.]
This record in other databases:
Please use a persistent id in citations: doi:10.1016/j.molmed.2023.04.005
Abstract: Mutations in the AT-interacting domain-rich protein 1A (ARID1A) gene, a critical component of the switch/sucrose nonfermentable (SWI/SNF) complex, are frequently found in most human cancers. Approximately 5-10% of lung cancers carry ARID1A mutations. ARID1A loss in lung cancer correlates with clinicopathological features and poor prognosis. Co-mutation of ARID1A and epidermal growth factor receptor (EGFR) results in the limited efficacy of EGFR tyrosine kinase inhibitors (EGFR-TKIs) but increases the clinical benefit of immune checkpoint inhibitors (ICIs). ARID1A gene mutation plays a role in cell cycle regulation, metabolic reprogramming, and epithelial-mesenchymal transition. We present the first comprehensive review of the relationship between ARID1A gene mutations and lung cancer and discuss the potential of ARID1A as a new molecular target.
Keyword(s): ARID1A ; SWI/SNF complex ; cell cycle regulation ; epithelial–mesenchymal transition ; lung cancer ; metabolic reprogramming
![]() |
The record appears in these collections: |